UHS: A Hospital Operator Trading at Half the Sector's Multiple

Universal Health Services (NYSE: UHS) closed at $170.67 on May 14, 2026 — down 31% from its November 2025 high of $246.33 and sitting just 12% above its 52-week low. 1 The market capitalization stands at roughly $10.3 billion, yet the trailing P/E is 7.12x — a multiple that implies either a business in structural decline or a valuation that has detached from the underlying fundamentals. Against the three screening criteria — ROE, free cash flow, and reasonable valuation — the data points toward the latter.

Universal Health Services, Inc. is one of the largest for-profit hospital operators in the United States, running two distinct platforms under one balance sheet. The acute care segment — 29 inpatient hospitals — generated approximately 57% of consolidated revenues in FY2025. The behavioral health segment — 346 inpatient psychiatric and substance abuse facilities and 168 outpatient sites — contributed roughly 43%. 2

The network spans 40 states, Washington D.C., the United Kingdom, and Puerto Rico, with roughly 101,500 employees. 3 FY2025 revenue reached $17.4 billion, placing UHS at #271 on the Fortune 500.

The dual-platform structure is operationally relevant: behavioral health demand tends to hold up or rise during economic downturns, which partially offsets the cyclical sensitivity of elective acute care volumes.

The channel's screening criterion requires ROE above 15% for each of the trailing three fiscal years. UHS is a borderline pass.

FY2023 ROE came in at 11.71% — below the 15% threshold, a consequence of the post-COVID labor cost spike that compressed net income to $717 million. 4 The picture shifted sharply from FY2024 onward: net income rebounded to $1.14 billion (ROE 17.38%), then hit a company record of $1.49 billion in FY2025 (ROE 20.88%), driven by volume recovery and operating leverage. 2 The TTM figure through March 2026 holds at 20.85%.

The trajectory matters as much as the snapshot. ROE more than doubled from FY2023 to FY2025, driven by net income growth of 107% outpacing equity growth of 16.5%. FY2026 full-year adjusted EPS guidance midpoint is $23.58 — consistent with the current profitability level.

All five measured periods show positive FCF.

FY2024 produced $1.12 billion in FCF on operating cash flow of $2.07 billion — the best year in the series. 5 FY2025 FCF pulled back to approximately $825 million as capital expenditure rose from $944 million to $1.04 billion — a planned increase tied to capacity expansion (178 new acute-care beds and 264 behavioral health beds). 6 The TTM figure (through March 2026) recovered to $913 million, with Q1 2026 alone contributing roughly $184 million in quarterly FCF ($402M operating cash flow minus $217M capex). 1

At the current market cap, TTM FCF yield is 8.83% — a figure that would usually indicate either cheap valuation or elevated reinvestment risk. Capex is rising intentionally; it is not a sign of operational distress.

Revenue has grown from $12.6 billion in FY2021 to $17.4 billion in FY2025, a five-year compound annual growth rate of approximately 8.3%. 7 Q1 2026 revenue of $4.50 billion grew 9.6% year over year, and the FY2026 guidance midpoint of $18.6 billion implies roughly 7% growth over FY2025. 2

Margins recovered from the labor-cost trough. Operating margin bottomed at 7.49% in FY2022 when labor cost inflation peaked, then expanded steadily: 8.23% (FY2023) → 10.62% (FY2024) → 11.48% (FY2025). 8 Net margin followed the same arc, reaching 8.57% in FY2025. CFO Steve Filton noted on the Q4 2025 earnings call that the headcount investments made in 2025 "will clearly moderate in 2026," suggesting operating leverage should hold. 9

UHS's trailing P/E of 7.12x sits roughly 39% below its own five-year average of approximately 11.74x and 43% below the peer group median. 610 The EV/EBITDA of 5.75x is 34% below its 10-year median of 8.74x. 11

The peer comparison table below uses data from StockAnalysis.com as of May 14, 2026. Note that HCA Healthcare and Community Health Systems (CYH) carry negative book equity — HCA from aggressive buybacks, CYH from accumulated losses — making P/B inapplicable for those two names; the P/B peer median shown covers only THC and EHC.

UHS trades at the lowest trailing P/E, forward P/E, and PEG among major hospital operators. The one metric where the discount narrows is EV/EBITDA, where THC (5.90x) and CYH (5.16x) sit close to UHS — though CYH has negative FCF and a highly leveraged balance sheet that makes the comparison of limited relevance.

A standard caveat applies to this valuation comparison: a persistent discount to peers often reflects a real risk premium, not a simple pricing error. The risks section below explains what the market is likely pricing in.

As of March 31, 2026, UHS carries $4.71 billion in total debt against $7.53 billion in total shareholders' equity — a debt-to-equity ratio of 62.5%, down from 64.8% at year-end 2025. 1 The current ratio is 1.08, thin but stable. TTM interest coverage (operating income / interest expense) is approximately 13.3x — comfortably above the 3x threshold typically associated with debt service risk.

The most immediate debt event is a $700 million, 1.65% senior note maturity on September 1, 2026. 15 In April 2026 UHS amended its credit agreement to add $900 million of borrowing capacity (revolving credit raised to $1.5 billion, term loan A raised to $1.455 billion, plus a new $400 million delayed-draw facility for the Talkspace acquisition), giving the company sufficient runway to refinance that maturity without equity dilution. 1

Credit ratings from Fitch and S&P both stand at BB+ Stable — one notch below investment grade. 16

UHS controls an estimated 20% of the U.S. private behavioral health inpatient market, operating approximately 330 behavioral facilities — the largest private operator in this segment. 3 In many of its key behavioral health markets, Certificate of Need (CON) laws require regulatory approval before competitors can open new facilities, creating a structural barrier to entry that protects existing market share.

On the cost side, corporate SG&A has consistently run below 5% of revenue in 2024-2025, below the industry average for for-profit hospital operators. 3 The company also maintains proprietary clinical programs for military personnel under contracts with the Department of Defense — a differentiated payer relationship not easily replicated at scale.

The dual-platform design (acute + behavioral) provides some counter-cyclical ballast: behavioral health volumes tend to rise during recessions, partially cushioning any downturn in elective acute procedures.

Three risk categories stand out and appear to be the primary drivers of the valuation discount.

Litigation exposure. As of November 2025, more than 30 lawsuits had been filed against UHS alleging sexual abuse of minors at the company's psychiatric facilities, including a December 2024 suit representing over 100 former patients at Hartgrove Hospital (Illinois) and other UHS sites. 17 The company's own FY2025 10-K states that the outcome of pending litigation, specifically naming Cumberland Hospital (Virginia) and Washoe County (Nevada) matters, "could have a material adverse effect on the Company." 18 For context: UHS paid $122 million in July 2020 to settle False Claims Act allegations and remains under a Corporate Integrity Agreement with HHS-OIG from that settlement. No public disclosure quantifies the potential dollar exposure of the current lawsuits.

Governance concentration. The Miller family — founder Alan B. Miller and President/CEO Marc D. Miller — controls 91.8% of total voting power through a dual-class share structure (Class A, B, and C shares). 19 Institutional shareholders hold economic stakes but effectively no governance influence. All insider transactions in the past six months were tax-withholding share deliveries coded Form 4 type "F" — no open-market purchases or discretionary sales.

Medicaid and ACA policy risk. Legislation enacted on July 4, 2025 attaches work and community service requirements to Medicaid eligibility, with UHS noting this "will have the effect of limiting Medicaid enrollment and expenditures." 18 Behavioral health providers are disproportionately exposed to Medicaid as a payer. UHS has not quantified the revenue impact in public guidance.

Short interest sits at 5.53–6.53% of float with approximately 3.2 days to cover — elevated but not extreme. 20

Q2 2026 earnings are expected July 26-27. UHS has beaten consensus EPS by an average of 8.2% over the last four quarters, but the stock fell 9.45% the day after its Q1 2026 beat. 21 That pattern — beat the number, sell the stock — has been consistent across recent reporting dates and is partly attributable to Medicaid policy uncertainty rather than anything operationally idiosyncratic to the quarter.

Talkspace acquisition. In March 2026, UHS agreed to acquire Talkspace (NASDAQ: TALK), a virtual behavioral health platform, for $5.25 per share in cash (~$835 million total). 18 The shareholder vote is scheduled for May 29, 2026. The deal extends UHS's behavioral health reach into digital/virtual care — a logical adjacency given the CON-constrained physical capacity ceiling.

Capital return. UHS paid $899.3 million in share repurchases during FY2025 (+50% vs. FY2024) and completed $127.3 million more in Q1 2026, with approximately $1.3 billion of buyback authorization remaining. 1 The quarterly dividend is $0.20/share ($0.80 annualized), yielding 0.47% at the current price — nominal income but evidence of commitment to returning cash.

Analyst consensus (19 analysts) stands at 8 Buy / 10 Hold / 1 Sell, with average 12-month price targets ranging from $212 (24/7 Wall St.) to $227 (MarketBeat) — implying 25-33% upside from $170.67. 22 Analyst price targets carry systematic upward bias; a standard caveat applies. The consensus rating is Hold, not Buy.

UHS is a profitable, cash-generative, moat-protected business trading at roughly half the valuation multiple of its primary peer, HCA Healthcare (NYSE: HCA, the largest for-profit hospital operator in the U.S. with 180+ hospitals and approximately 25% of the for-profit market). The discount is real — but so are the reasons for it.

The litigation risk is unquantified and open-ended: the $122 million FCA settlement in 2020 provides a lower-bound data point, but the current wave involves patient harm allegations of a different character. The Miller family's near-total voting control means minority shareholders have no mechanism to influence governance if the litigation trajectory worsens. And Medicaid policy is evolving in a direction that reduces the eligible population for UHS's highest-margin behavioral health segment.

Against that: the operating fundamentals — revenue growth, margin expansion, FCF generation, interest coverage — are moving in the right direction. The balance sheet is not distressed. The upcoming catalysts with specific dates are Q2 earnings (July 26-27) and the Talkspace shareholder vote (May 29). If litigation exposure becomes more quantifiable — through filings, settlements, or reserve disclosures in the next 10-Q — that single variable could move the stock materially in either direction.